Loading publications…
The last 5 uploaded publications
Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials
Raghava Kashyap, James Buteau, Mathias Bressel, Michal Eifer, Neeraja Bollampally, Price Jackson, Lachlan McIntosh, Shahneen Sandhu, Michael S. Hofman (2025). Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials. , DOI: https://doi.org/10.2967/jnumed.125.269640.
Article63 days agoLuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).
Shahneen Sandhu, Anthony M. Joshua, Louise Emmett, Megan Crumbaker, Mathias Bressel, Rhonda Huynh, Patricia Banks, Roslyn Wallace, Anis Hamid, Andrisha Jade Inderjeeth, Ben Tran, Arun Azad, Ramin Alipour, Grace Kong, Aravind Ravi Kumar, Javad Saghebi, Scott Williams, Timothy Akhurst, Rodney J. Hicks, Michael S. Hofman (2023). LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).. , 41(16_suppl), DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.5005.
Article63 days agoAdministering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study
Renu Eapen, James Buteau, Price Jackson, Catherine Mitchell, Sheng F. Oon, Omar Alghazo, Lachlan McIntosh, Nattakorn Dhiantravan, Mark Scalzo, J O’Brien, Shahneen Sandhu, Arun Azad, Scott Williams, Gaurav Sharma, Mohammad B. Haskali, Mathias Bressel, Kenneth Chen, Pocharapong Jenjitranant, Aoife McVey, Daniel Moon, Nathan Lawrentschuk, Paul J. Neeson, Declan G. Murphy, Michael S. Hofman (2023). Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study. , 85(3), DOI: https://doi.org/10.1016/j.eururo.2023.08.026.
Article63 days agoAdministering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study
Renu Eapen, James Buteau, Price Jackson, Catherine Mitchell, Sheng F. Oon, Omar Alghazo, Lachlan McIntosh, Nattakorn Dhiantravan, Mark Scalzo, J O’Brien, Shahneen Sandhu, Arun Azad, Scott Williams, Gaurav Sharma, Mohammad B. Haskali, Mathias Bressel, Kenneth Chen, Pocharapong Jenjitranant, Aoife McVey, Daniel Moon, Nathan Lawrentschuk, Paul J. Neeson, Declan G. Murphy, Michael S. Hofman (2023). Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study. , 85(3), DOI: https://doi.org/10.1016/j.eururo.2023.08.026.
Article63 days agoPRINCE: Phase I trial of <sup>177</sup>Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).
Shahneen Sandhu, Anthony M. Joshua, Louise Emmett, Lavinia Spain, Lisa G. Horvath, Megan Crumbaker, A. Antón, Roslyn Wallace, Anupama Pasam, Mathias Bressel, E. Cassidy, Patricia Banks, Nattakorn Dhiantravan, Timothy Akhurst, Aravind Ravi Kumar, Ramin Alipour, Mark Scalzo, Scott Williams, Rodney J. Hicks, Michael S. Hofman (2022). PRINCE: Phase I trial of <sup>177</sup>Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).. , 40(16_suppl), DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.5017.
Article63 days ago